PL4182311T3 - Pochodne 1-metylo-1h-pirazol-3-ilu do zastosowania w leczeniu chorób neowaskularnych - Google Patents

Pochodne 1-metylo-1h-pirazol-3-ilu do zastosowania w leczeniu chorób neowaskularnych

Info

Publication number
PL4182311T3
PL4182311T3 PL21748927.7T PL21748927T PL4182311T3 PL 4182311 T3 PL4182311 T3 PL 4182311T3 PL 21748927 T PL21748927 T PL 21748927T PL 4182311 T3 PL4182311 T3 PL 4182311T3
Authority
PL
Poland
Prior art keywords
pyrazol
derivatives
methyl
treatment
neovascular diseases
Prior art date
Application number
PL21748927.7T
Other languages
English (en)
Inventor
Andrew Douglas Baxter
Jonathan Morris
Original Assignee
Exonate Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exonate Limited filed Critical Exonate Limited
Publication of PL4182311T3 publication Critical patent/PL4182311T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL21748927.7T 2020-07-14 2021-07-14 Pochodne 1-metylo-1h-pirazol-3-ilu do zastosowania w leczeniu chorób neowaskularnych PL4182311T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2010829.6A GB202010829D0 (en) 2020-07-14 2020-07-14 Compounds for treatment of neovascular diseases
PCT/GB2021/051810 WO2022013555A1 (en) 2020-07-14 2021-07-14 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases

Publications (1)

Publication Number Publication Date
PL4182311T3 true PL4182311T3 (pl) 2025-11-12

Family

ID=72139988

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21748927.7T PL4182311T3 (pl) 2020-07-14 2021-07-14 Pochodne 1-metylo-1h-pirazol-3-ilu do zastosowania w leczeniu chorób neowaskularnych

Country Status (23)

Country Link
US (2) US12024504B2 (pl)
EP (1) EP4182311B1 (pl)
JP (1) JP7827690B2 (pl)
KR (1) KR20230052890A (pl)
CN (1) CN116075506B (pl)
AU (1) AU2021309894A1 (pl)
BR (1) BR112023000571A2 (pl)
CA (1) CA3183466A1 (pl)
DK (1) DK4182311T3 (pl)
ES (1) ES3039003T3 (pl)
FI (1) FI4182311T3 (pl)
GB (1) GB202010829D0 (pl)
HR (1) HRP20250955T1 (pl)
HU (1) HUE072558T2 (pl)
LT (1) LT4182311T (pl)
MX (1) MX2023000570A (pl)
PL (1) PL4182311T3 (pl)
PT (1) PT4182311T (pl)
RS (1) RS67158B1 (pl)
SI (1) SI4182311T1 (pl)
SM (1) SMT202500307T1 (pl)
WO (1) WO2022013555A1 (pl)
ZA (1) ZA202301105B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202010829D0 (en) * 2020-07-14 2020-08-26 Exonate Ltd Compounds for treatment of neovascular diseases
CN120917015A (zh) * 2023-01-20 2025-11-07 元启(苏州)生物制药有限公司 Srpk1抑制剂和使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60235761D1 (de) 2001-08-01 2010-05-06 Univ Bristol Clifton Isoform des vegfs
US7569536B2 (en) 2003-12-26 2009-08-04 Masatoshi Hagiwara Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity
JP5182088B2 (ja) * 2006-04-19 2013-04-10 アステラス製薬株式会社 アゾールカルボキサミド誘導体
GB0704678D0 (en) 2007-03-09 2007-04-18 Univ Bristol Pro- and anti-angiogenic treatments
GB0803912D0 (en) 2008-02-29 2008-05-07 Univ Bristol Novel Uses of VEGFxxxb
JP2012509306A (ja) 2008-11-22 2012-04-19 ザ ユニバーシティ オブ ブリストル VEGFxxxbの新規な使用
GB201009173D0 (en) 2010-05-28 2010-07-14 Univ Bristol Treatment of pain
JP2016504270A (ja) 2012-10-17 2016-02-12 ザ ユニバーシティ オブ ブリストル 眼血管形成(ocularneovasculan)を治療するのに有用な化合物
GB201406956D0 (en) 2014-04-17 2014-06-04 Univ Nottingham Compounds
GB201518365D0 (en) 2015-10-16 2015-12-02 Exonate Ltd Compounds
PT3266446T (pt) * 2016-07-07 2019-01-30 Salvat Lab Sa Composição oftálmica compreendendo óleo de rícino e triglicérido de cadeia média
WO2019063996A1 (en) 2017-09-27 2019-04-04 Exonate Limited INHIBITORS OF SRPK1
EP3691112B1 (en) 2017-09-29 2022-06-22 Hitachi Industrial Equipment Systems Co., Ltd. Data obtaining method, inverter, and rotating electric machine
GB202010829D0 (en) * 2020-07-14 2020-08-26 Exonate Ltd Compounds for treatment of neovascular diseases

Also Published As

Publication number Publication date
HRP20250955T1 (hr) 2025-10-10
FI4182311T3 (fi) 2025-08-22
RS67158B1 (sr) 2025-09-30
MX2023000570A (es) 2023-04-19
JP2023535157A (ja) 2023-08-16
US12024504B2 (en) 2024-07-02
CA3183466A1 (en) 2022-01-20
AU2021309894A1 (en) 2023-03-09
GB202010829D0 (en) 2020-08-26
EP4182311B1 (en) 2025-06-04
JP7827690B2 (ja) 2026-03-10
DK4182311T3 (da) 2025-08-25
SI4182311T1 (sl) 2025-11-28
ES3039003T3 (en) 2025-10-16
CN116075506A (zh) 2023-05-05
US20240300929A1 (en) 2024-09-12
HUE072558T2 (hu) 2025-11-28
WO2022013555A1 (en) 2022-01-20
BR112023000571A2 (pt) 2023-01-31
EP4182311A1 (en) 2023-05-24
CN116075506B (zh) 2025-10-10
ZA202301105B (en) 2025-07-30
PT4182311T (pt) 2025-08-27
LT4182311T (lt) 2025-09-25
US20220411412A1 (en) 2022-12-29
KR20230052890A (ko) 2023-04-20
SMT202500307T1 (it) 2025-11-10

Similar Documents

Publication Publication Date Title
IL285269A (en) Compositions and methods for treating neurocognitive disorders
IL285270A (en) Compositions and methods for treating neurocognitive disorders
HUE058931T2 (hu) Pilokarpin hidroklorid alkalmazása presbyopia kezelésére
PL3429571T3 (pl) Kombinacje inhibitorów lsd1 do zastosowania w leczeniu chorób nowotworowych
IL287957A (en) Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma
IL287796A (en) Compositions and methods for the treatment of atpase-mediated diseases
IL285708A (en) Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
PL4076652T3 (pl) Farmaceutycznie dopuszczalna sól atrasentanu do zastosowania w sposobie leczenia nefropatii iga
HUE060322T2 (hu) Belélegezhetõ készítmények tüdõbetegségek kezelése során történõ alkalmazásra
IL281244A (en) Combination therapy for the treatment of liver disease
EP3347010A4 (en) SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER
HUE058151T2 (hu) Enterococcusból származó flagellin készítményei terápiában történõ alkalmazásra
MA46608A (fr) Formulation liposomale destinée à être utilisée dans le traitement du cancer
IL287704A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
IL290891A (en) Compositions and methods of treating vascular diseases
IL311638A (en) Compositions and methods for treating cag repeat diseases
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
MA47111A (fr) Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
EP4203928A4 (en) Inhalable therapeutic agents
IL292186A (en) Compositions and methods for treating blood disorders
PL4182311T3 (pl) Pochodne 1-metylo-1h-pirazol-3-ilu do zastosowania w leczeniu chorób neowaskularnych
IL248468A0 (en) Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing
IL285268A (en) Compositions and methods for treating neurocognitive disorders
IL272194A (en) Multispecific antibodies for use in treating diseases